Anti-inflammatory hydrolysate of
View Patent ↗Methods and compositions for reducing and/or inhibiting inflammation by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Coriolus versicolor that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei, and thereafter rendered substantially devoid of acid-protease activity.
1. A topical anti-inflammatory mushroom hydrolysate substantially devoid of acid protease activity produced by the steps of (a) extracting Coriolus versicolor in an acidic aqueous solvent having a pH of from about 3.5 to about 4.5 to form a water-soluble polysaccharopeptide extract, (b) hydrolyzing the water-soluble polysaccharopeptide extract with an acid protease enzyme of Rhizomucor miehei and, (c) inactivating or removing the acid protease via molecular weight sieve, thermal inactivation and/or pepstatin-affinity gel chromatography.
2. The topical anti-inflammatory mushroom hydrolysate substantially devoid of acid protease activity according to claim 1 wherein the acid protease enzyme of Rhizomucor miehei used to hydrolyze the water-soluble polysaccharo-peptide extract of Coriolus versicolor has from about 4,000 to about 10,000 HUT units of activity per milliliter.
3. A dermatocosmetic composition comprising from about 0.01% to about 10% by weight of the topical anti-inflammatory mushroom hydrolysate according to claim 1 .
4. A dermatocosmetic composition comprising the topical anti-inflammatory mushroom hydrolysate according to claim 1 , further comprising at least one additional topical anti-inflammatory agent.
5. The dermatocosmetic composition of claim 4 wherein the at least one additional topical anti-inflammatory agent is a non-steroidal anti-inflammatory drug.
6. The dermatocosmetic composition of claim 4 wherein the at least one additional topical anti-inflammatory agent is hydrocortisone.
7. A method for inhibiting the production of COX-2 enzymes comprising applying to the skin of a mammal a therapeutically-effective amount of the topical anti-inflammatory mushroom hydrolysate according to claim 1 .
8. The method of claim 7 , wherein the topical anti-inflammatory mushroom hydrolysate of claim 1 is applied in a concentration sufficient to reduce the expression of mRNA coding for PTGS2 by at least about 50%.
9. The method of claim 7 , wherein the topical anti-inflammatory mushroom hydrolysate of claim 1 is applied in a concentration sufficient to reduce the expression of mRNA coding for PTGS2 by at least about 67%.